Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

Uropathologists, for the first time, acknowledge issues with indolent Grade Group 1 tumors, which are leading to ...

Omitting endocrine therapy in ER-low breast cancer was associated with a 23% relative increase in the risk of death in 3 ...

Brain Pathway Links Inflammation to Loss of Motivation, Energy in Advanced Cancer Apr. 10, 2025 — Researchers identified a direct connection between cancer-related inflammation and the loss of ...

Physicians classify brain tumors and determine treatment options, in part, by the genes they express. According to World Health Organization standards, the abnormal activation of oncogene FOXR2 ...

Listening to the news can feel like a journey. But 1A guides you beyond the headlines – and cuts through the noise. Let's get to the heart of the story, together – on 1A.

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.